University of Minnesota - Masonic Cancer Center
Minneapolis, MN
Not yet accepting
QUINTESSENTIAL-2
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
- CAR T Cell
- CD19
- BCMA
- Phase 1/2
- Has results
Accepting patients
IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Natural Killer Cells (Allogeneic)
- Phase 1/2
3 hidden based on your filters.Show All